GlobeNewswire

Aptean Extends Its Leadership in the Manufacturing ERP Market With Acquisition of OPTIWARE

Share

ATLANTA, May 02, 2019 (GLOBE NEWSWIRE) -- Aptean, a global provider of mission-critical enterprise software solutions, has acquired OPTIWARE, a leading provider of Overall Equipment effectiveness (OEE) and Enterprise Asset Management (EAM) solutions. The acquisition of OPTIWARE extends Aptean’s capabilities in European marketplaces, a key growth area for the company.

OPTIWARE’s products deliver productivity improvements and optimal utilization of production resources and support the transition of global enterprises towards Industry 4.0 and Smart Manufacturing. Supplying the connection of production equipment and powerful tools for efficiency monitoring, together with one of the most flexible EAM solutions available in the market today.

“The European market is a key strategic growth area for Aptean,” said TVN Reddy, Aptean CEO. “OPTIWARE’s capabilities will forward our growth strategy both in our manufacturing solution suite and in European markets where we’ve targeted for expansion. With their strong focus on efficiency, reliability and productivity we believe that OPTIWARE is an ideal fit with our solution offerings. Aptean now offers a more complete suite of solutions for manufacturers in specific verticals such as food and beverage, chemical, automotive, pharmaceutical, and other manufacturing segments. We are delighted to welcome OPTIWARE to the Aptean family”.

“At OPTIWARE we believe that state-of-the-art functionality, visibility and mobility are prerequisites for catering to our customer’s needs – and that our understanding, experience and forward-thinking is what makes the real difference.” said Michael Ries, CEO of OPTIWARE. “By joining Aptean and becoming part of a larger organization, we’ll access their considerable capabilities and will benefit from Aptean’s expertise in the market. We are excited to join the Aptean team”.

“OPTIWARE has realized a strong growth in both revenue and earnings during our ownership and the company is well positioned to benefit from the increasing digitalization and the Industry 4.0 transformation. After approximately six years ownership, we therefore believe it is time to divest OPTIWARE to a new owner. Based on the experiences and talks during the M&A process, we believe that Aptean is the right partner for OPTIWARE to continue the growth journey.” said Erik Balleby Jensen, CEO and Partner in Capidea and Chairman of OPTIWARE.

Headquartered in Denmark, OPTIWARE has approximately 100 team members across offices in Europe, Asia and the United States who will become part of the Aptean organization. Financial terms of the sale will not be disclosed.

About OPTIWARE
OPTIWARE is the result of the merger between API Maintenance Systems and AXXOS Industry Systems. We help customers streamline their production and maintain high-value capital assets such as plants, facilities and equipment. OPTIWARE is a global company helping customers to gain an edge by optimizing asset reliability, predictability and effectiveness. We do this by offering a unique combination of both Enterprise Asset Management (EAM) and Overall Equipment Effectiveness (OEE) systems. OPTIWARE has supplied the production monitoring solutions AXXOS OEE and the EAM solution API PRO for more than 25 years. OPTIWARE is headquartered in Denmark and has over 500 customers globally.

About Aptean
Aptean is a global provider of mission-critical, industry-specific software solutions. Aptean’s purpose-built ERP and supply chain management solutions help address the unique challenges facing process and discrete manufacturers, distributors, and other focused organizations. Aptean’s compliance solutions are built for companies serving specific markets such as finance, healthcare, biotech and pharmaceuticals. Over 2,500 organizations in more than 20 industries across 54 countries trust Aptean’s solutions at their core to assist with running their operations. To learn more about Aptean and the markets we serve, visit www.aptean.com.

Aptean is a trademark of Aptean, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.

About Capidea
Capidea is a Danish private equity fund making long term investments in competitive small and medium-sized companies. Capidea was established in November 2006 and has a total capital commitment of approximately DKK 2.3 billion / EUR 310 million in three funds. Capidea’s third fond was established in December 2017 with a capital commitment of DKK 860 million / EUR 115 million. In addition to institutional investors, the investor base comprises a number of bluechip companies. Capidea has invested in 19 companies with a total turnover of approx. DKK 5 billion/EUR 670 million, visit www.capidea.dk.


FOR MORE INFORMATION

APTEAN
Media Relations
Mark Pileski
mark.pileski@aptean.com
+1 647.499.6583

OPTIWARE
Michael Ries, CEO
michael.ries@optiware.com
+45 40 27 99 41

CAPIDEA
Erik Balleby Jensen, CEO & Partner
ebj@capidea.dk
+45 21 23 33 36

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi

SERSTECH AB: Half-year report 1 January – 30 June 201920.8.2019 08:45:00 CESTPress release

SALES INCREASE BY 200% FROM HIGHER MARKET ACCEPTANCE Second quarter 2019 Period 1 January - 30 June 2019 • Net sales: KSEK 5 089 (1 558, +227%) • Net sales: KSEK 8 340 (2 768, +201%) • Profit for the period: KSEK -3 349 (-2 166) • Profit for the period KSEK -7 008 (-5 599) • Earnings per share SEK -0,05 (-0,03) • Earnings per share: SEK -0,11 (-0,09) During Q2, we passed another set of important milestones on our way to becoming a significant player in the security industry and a more mature, professional organization. Our net sales numbers continued to move in the right direction, +227% compared to Q2 2018, and we received significant orders, expanded the reach of our sales network and signed another OEM agreement. We dramatically expanded our R&D capabilities and added dedicated roles for product management and quality assurance, both of which are imperative as our volumes continue to increase. Our operative cash flow continues to improve and for the first half of the year our operat

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso20.8.2019 08:00:00 CESTPress release

Metso Corporation, Stock exchange release on August 20, 2019, at 9:00 a.m. EEST Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the holding of mutual funds managed by BlackRock, Inc. of the total amount of shares and financial instruments entitling to shares of Metso. On August 16, 2019, BlackRock Inc.'s direct holding in Metso shares and in financial instruments entitling to shares fell below the 5 percent threshold. On August 14, 2019, BlackRock, Inc.'s total position in Metso amounted to less than 5 percent of Metso’s shares and votes. Metso’s total number of shares and votes is 150,348,256. BlackRock, Inc.’s holdings according to the notification: % of shares and voting rights (A) % of shares and voting rights through financial instruments (B) Total of both in % (A + B) Res

Intention to list & Company Description20.8.2019 08:00:00 CESTPress release

GG St. Kongensgade 100 og 106 P/S Nasdaq First North, Copenhagen, Bond Market Ticker: GGSTK; ISIN: DK0030444401 For release: 20 August 2019 Intention to list the company’s floating rate (7%) secured bond loan 2019/2020 and company description The Director of GG St. Kongensgade 100 og 106 P/S announces that the Company intends to list its floating rate 7% secured bond loan 2019/2020 for trading on Nasdaq First North, Copenhagen. In connection with this, the Company has prepared a Company Description which has been approved by Nasdaq Copenhagen A/S. A copy of the Company Description accompanies this release and it may also be downloaded from the Investor Relations section of the Company’s website at www.gefiongroup.com The Company anticipates the first day of trading in its Bonds being 23 August 2019. GG St. Kongensgade 100 og 106 P/S, incorporated under the laws of Denmark with business registration number 38 30 68 47, having its registered office at c/o Gefion Group A/S, Østergade 1, 2